Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001233912 | SCV001406527 | pathogenic | Hereditary spastic paraplegia 11 | 2023-01-03 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 960397). This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (HSP) (PMID: 27544499; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.His1717Thrfs*3) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005012652 | SCV005637881 | pathogenic | Amyotrophic lateral sclerosis type 5; Hereditary spastic paraplegia 11; Charcot-Marie-Tooth disease axonal type 2X | 2024-06-17 | criteria provided, single submitter | clinical testing | |
Genomics England Pilot Project, |
RCV001233912 | SCV001760345 | likely pathogenic | Hereditary spastic paraplegia 11 | no assertion criteria provided | clinical testing |